Molecular adaptation to chronic antidepressant treatment: Evidence for a more rapid response to the novel α 2-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine

International Journal of Neuropsychopharmacology

Volumn 15, Issue 5, 2012, Pages 617-629

  Serres, Florence ^a   Millan, Mark J ^b   Sharp, Trevor ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

2 adrenoceptor; Antidepressant; neural plasticity; S35966; venlafaxine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; PROTEIN HOMER 1A; PROTEIN SHANK 1B; S 35966; UNCLASSIFIED DRUG; VENLAFAXINE; VESICULAR GLUTAMATE TRANSPORTER 1;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; GENE; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; IN SITU HYBRIDIZATION; MALE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SHANK1B GENE; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CEREBRAL CORTEX; CYCLOHEXANOLS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTONIN; TIME FACTORS;

EID: 84861084026     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000733     Document Type: Article

References (79)

1. Altar CA, Vawter MP, Ginsberg SD (2009). Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 34, 18-54.
2. Andres JI, Alcazar J, Alonso JM, Alvarez RM, et al. (2005). Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. Journal of Medicinal Chemistry 48, 2054-2071. (Pubitemid 40396333)
3. Benedetti F, Radaelli D, Bernasconi A, Dallaspezia S, et al. (2009). Changes in medial prefrontal cortex neural responses parallel successful antidepressant combination of venlafaxine and light therapy. Archives Italiennes de Biologie 147, 83-93.
4. Bertaso F, Roussignol G, Worley P, Bockaert J, et al. (2010). Homer1a-dependent crosstalk between NMDA and metabotropic glutamate receptors in mouse neurons. PLoS One 5, e9755.
5. Blier P, Ward HE, Tremblay P, Laberge L, et al. (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder : a double-blind randomized study. American Journal of Psychiatry 167, 281-288.
6. Bramham CR (2008). Local protein synthesis, actin dynamics, and LTP consolidation. Current Opinions in Neurobiology 18, 524-531.
7. Bramham CR, Alme MN, Bittins M, Kuipers SD, et al. (2010). The Arc of synaptic memory. Experimental Brain Research 200, 125-140.
8. Cappiello A, McDougle CJ, Malison RT, Heninger GR, et al. (1995). Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biological Psychiatry 38, 765-767.
9. Castren E (2005). Is mood chemistry? Nature Reviews Neuroscience 6, 241-246. (Pubitemid 40342418)
10. Castro E, Tordera RM, Hughes ZA, Pei Q, Sharp T (2003). Use of Arc expression as a molecular marker of increased postsynaptic 5-HT function after SSRI/5-HT1A receptor antagonist co-administration. Journal of Neurochemistry 85, 1480-1487. (Pubitemid 36702560)
11. Conti B, Maier R, Barr AM, Morale MC, et al. (2007). Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Molecular Psychiatry 12, 167-189. (Pubitemid 46160982)
12. Coppell AL, Pei Q, Zetterstrom TS (2003). Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44, 903-910. (Pubitemid 36515026)
13. Cordi AA, Berque-Bestel I, Persigand T, Lacoste JM, et al. (2001). Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties. Journal of Medicinal Chemistry 44, 787-805. (Pubitemid 32171675)
14. Covington 3rd HE, Lobo MK, Maze I, Vialou V, et al. (2010). Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. Journal of Neuroscience 30: 16082-16090.
15. Cryan JF, Slattery DA (2007). Animal models of mood disorders : recent developments. Current Opinion in Psychiatry 20: 1-7. (Pubitemid 44901068)
16. D'Sa C, Duman RS (2002). Antidepressants and neuroplasticity. Bipolar Disorder 4, 183-194. (Pubitemid 34591244)
17. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, et al. (2004). Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128, 597-604. (Pubitemid 39277429)
18. Dell'aversano C, Tomasetti C, Iasevoli F, de Bartolomeis A (2009). Antipsychotic and antidepressant co-treatment : effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Research Bulletin 79, 123-129.
19. Deng W, Aimone JB, Gage FH (2010). New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nature Reviews Neuroscience 11, 339-350.
20. Dhir A, Kulkarni SK (2007). Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 80, 239-243. (Pubitemid 47557257)
21. Drevets WC (2001). Neuroimaging and neuropathological studies of depression: implications for the cognitiveemotional features of mood disorders. Current Opinion in Neurobiology 11, 240-249. (Pubitemid 32289413)
22. Drigues N, Poltyrev T, Bejar C, Weinstock M, et al. (2003). cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. Journal of Neural Transmission 110, 1413-1436. (Pubitemid 38041347)
23. Duman RS (2002). Synaptic plasticity and mood disorders. Molecular Psychiatry 7 (Suppl. 1), S29-S34. (Pubitemid 34280646)
24. Dwyer JM, Platt BJ, Rizzo SJ, Pulicicchio CM, et al. (2010). Preclinical characterization of BRL 44408: antidepressantand analgesic-like activity through selective alpha2A-adrenoceptor antagonism. International Journal of Neuropsychopharmacology 13, 1193-1205.
25. Elizalde N, Pastor PM, Garcia-Garcia AL, Serres F, et al. (2010). Regulation of markers of synaptic function in mouse models of depression: chronic mild stress and decreased expression of VGLUT1. Journal of Neurochemistry 114, 1302-1314.
26. Frazer A, Morilak DA (2005). What should animal models of depression model? Neuroscience Biobehavioral Reviews 29, 515-523. (Pubitemid 40762597)
27. Fuchs E, Czeh B, Kole MH, Michaelis T, et al. (2004). Alterations of neuroplasticity in depression: the hippocampus and beyond. European Neuropsychopharmacology 14 (Suppl. 5), S481-S490. (Pubitemid 39531609)
28. Gobert A, Cussac D, Lejeune F, Newman-Tancredi A, et al. (2002). The novel antidepressant, S35966, is a mixed serotonin and noradrenaline reuptake inhibitor and an antagonist at alpha2-adrenoceptors. European Neuropsychopharmacology 12 (Suppl. 3), S248.
29. Gobert A, Rivet JM, Cistarelli L, Melon C, et al. (1997). Alpha2-adrenergic receptor blockade markedly potentiates duloxetine-and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. Journal of Neurochemistry 69, 2616-2619. (Pubitemid 27495451)
30. Gubits RM, Smith TM, Fairhurst JL, Yu H (1989). Adrenergic receptors mediate changes in c-fos mRNA levels in brain. Brain Research. Molecular Brain Research 6, 39-45. (Pubitemid 19163715)
31. Invernizzi RW, Garattini S (2004). Role of presynaptic alpha2-adrenoceptors in antidepressant action : recent findings from microdialysis studies. Progress in Neuropsychopharmacology and Biological Psychiatry 28, 819-827. (Pubitemid 39195273)
32. Ioannidis JP, Allison DB, Ball CA, Coulibaly I, et al. (2009). Repeatability of published microarray gene expression analyses. Nature Genetics 41, 149-155.
33. Iwamoto K, Kato T (2006). Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 12, 349-361. (Pubitemid 44050863)
34. Jaubert PJ, Golub MS, Lo YY, Germann SL, et al. (2007). Complex, multimodal behavioral profile of the Homer1 knockout mouse. Genes Brain Behavior 6, 141-154. (Pubitemid 46328585)
35. Katz MM, Tekell JL, Bowden CL, Brannan S, et al. (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29, 566-579. (Pubitemid 38365934)
36. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, et al. (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45, 935-944. (Pubitemid 37297919)
37. Krishnan V, Berton O, Nestler E (2008). The use of animal models in psychiatric research and treatment. American Journal of Psychiatry 165, 1109.
38. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455, 894-902.
39. Liu RJ, Aghajanian GK (2008). Stress blunts serotonin-and hypocretin-evoked EPSCs in prefrontal cortex : role of corticosterone-mediated apical dendritic atrophy. Proceedings of the National Academy of Sciences USA 105, 359-364.
40. Lominac KD, Oleson EB, Pava M, Klugmann M, et al. (2005). Distinct roles for different Homer1 isoforms in behaviors and associated prefrontal cortex function. Journal of Neuroscience 25, 11586-11594. (Pubitemid 43098451)
41. Malberg JE, Schechter LE (2005). Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Current Pharmaceutical Design 11, 145-155. (Pubitemid 40089838)
42. Manji HK, Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nature Medicine 7, 541-547. (Pubitemid 32448319)
43. Mathew SJ, Manji HK, Charney DS (2008). Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33, 2080-2092. (Pubitemid 351992096)
44. McEwen BS, Chattarji S, Diamond DM, Jay TM, et al. (2010). The neurobiological properties of tianeptine (Stablon) : from monoamine hypothesis to glutamatergic modulation. Molecular Psychiatry 15, 237-249.
45. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states : conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 110, 135-370.
46. Millan MJ (2009). Dual-and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6, 53-77.
47. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, et al. (2001a). S33005, a novel ligand at both serotonin and norepinephrine transporters : II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. Journal of Pharmacology & Experimental Therapeutics 298, 581-591. (Pubitemid 32673408)
48. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, et al. (2001b). S33005, a novel ligand at both serotonin and norepinephrine transporters : I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. Journal of Pharmacology & Experimental Therapeutics 298, 565-580. (Pubitemid 32673407)
49. Millan MJ, Lejeune F, Gobert A, Newman-Tancredi A, et al. (2001c). The novel, potential antidepressant agents, S35966 and S35967, interact both with alpha2-adrenoceptors and with serotonin and norepinephrine transporters. European Neuropsychopharmacology 11, S196-S196.
50. Millan MJ, Lejeune F, Gobert A (2000). Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex : relevance to the actions of antidepressant agents. Journal of Psychopharmacology 14, 114-138. (Pubitemid 30389486)
51. Moutsimilli L, Farley S, Dumas S, El Mestikawy S, et al. (2005). Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49, 890-900. (Pubitemid 41483895)
52. Naisbitt S, Kim E, Tu JC, Xiao B, et al. (1999). Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23, 569-582. (Pubitemid 29359927)
53. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience 15, 7539-7547.
54. Ortega JE, Fernandez-Pastor B, Callado LF, Meana JJ (2010). In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by alpha(2)-adrenoceptor antagonism. European Neuropsychopharmacology 20, 813-822.
55. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, et al. (2006). A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology 26, 56-60. (Pubitemid 43167092)
56. Pei Q, Tordera R, Sprakes M, Sharp T (2004). Glutamate receptor activation is involved in 5-HT(2) agonist-induced Arc gene expression in the rat cortex. Neuropharmacology 46, 331-339. (Pubitemid 38223866)
57. Pei Q, Zetterstrom TS, Sprakes M, Tordera R, et al. (2003). Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience 121, 975-982. (Pubitemid 37324596)
58. Pizzagalli DA (2011). Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36, 183-206.
59. Ren-Patterson RF, Cochran LW, Holmes A, Lesch KP, et al. (2006). Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cellular and Molecular Neurobiology 26, 755-780.
60. Roussignol G, Ango F, Romorini S, Tu JC, et al. (2005). Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. Journal of Neuroscience 25, 3560-3570.
61. Sanacora G, Berman RM, Cappiello A, Oren DA, et al. (2004). Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology 29, 1166-1171. (Pubitemid 38670053)
62. Santarelli L, Saxe M, Gross C, Surget A, et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809. (Pubitemid 36962615)
63. Scheuerecker J, Meisenzahl EM, Koutsouleris N, Roesner M, et al. (2010). Orbitofrontal volume reductions during emotion recognition in patients with major depression. Journal of Psychiatry & Neuroscience 35, 311-320.
64. Sequeira A, Turecki G (2006). Genome wide gene expression studies in mood disorders. Omics 10, 444-454. (Pubitemid 46174578)
65. Serres F, Millan MJ, Sharp T (2006). The dual alpha2-adrenoceptor antagonist and monoamine reuptake inhibitor, S35966, rapidly induces Arc gene expression in rat cortex and hippocampus. Abstracts of Meeting of the Federation of European Neuroscience Societies 3, A166. 115.
66. Serres F, Millan MJ, Wakefield L, Sharp T (2010). Decreases in molecular markers of synaptic plasticity in the chronic social defeat model of depression. Abstracts of Meeting of the Federation of European Neuroscience Societies 5, 017. 38.
67. Sillaber I, Panhuysen M, Henniger MS, Ohl F, et al. (2008). Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berlin) 200, 557-572.
68. Soumier A, Ouealati A, Millan MJ, Daszuta A (2006). Induction of hippocampal neurogenesis by the novel antidepressant, S35966, a combined alpha2 adrenoceptor (AR) antagonist and monoamine reuptak inhibitor. American Society for Neuroscience 32, 828. 7.
69. Stone EA, Lin Y, Quartermain D (2008). Evaluation of the repeated open-space swim model of depression in the mouse. Pharmacology Biochemistry and Behaviour 91, 190-195.
70. Szumlinski KK, Ary AW, Lominac KD (2008). Homers regulate drug-induced neuroplasticity: implications for addiction. Biochemical Pharmacology 75, 112-133. (Pubitemid 350235395)
71. Thase ME (2008). Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacology Bulletin 41, 58-85.
72. Tordera RM, Pei Q, Sharp T (2005). Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. Journal of Neurochemistry 94, 875-883. (Pubitemid 41170576)
73. Townsend JD, Eberhart NK, Bookheimer SY, Eisenberger NI, et al. (2010). fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder. Psychiatry Research 183, 209-217.
74. Tsankova NM, Berton O, Renthal W, Kumar A, et al. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience 9, 519-525.
75. Tu JC, Xiao B, Naisbitt S, Yuan JP, et al. (1999). Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23, 583-592. (Pubitemid 29359928)
76. van den Broek WW, Mulder PG, van Os E, Birkenhager TK, et al. (2009). Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder : a meta-analysis. Journal of Psychopharmacology 23, 708-713.
77. Witkin JM, Li X (2009). New approaches to the pharmacological management of major depressive disorder. Advances in Pharmacology 57, 347-379.
78. Yanpallewar SU, Fernandes K, Marathe SV, Vadodaria KC, et al. (2010). Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. Journal of Neuroscience 30, 1096-1109.
79. Zarate C, Machado-Vieira R, Henter I, Ibrahim L, et al. (2010). Glutamatergic modulators : the future of treating mood disorders? Harvard Review of Psychiatry 18, 293-303.